Review



p nf κb signaling pathway activator pma  (Selleck Chemicals)


Bioz Verified Symbol Selleck Chemicals is a verified supplier
Bioz Manufacturer Symbol Selleck Chemicals manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 96

    Structured Review

    Selleck Chemicals p nf κb signaling pathway activator pma
    Nicotine reduces the sensitivity of colon cancer cells to oxaliplatin through modulation of the HMOX1/NF-κB signaling pathway. a-b The CCK-8 assay demonstrated that 10 µM oxaliplatin treatment for 24 h significantly inhibited the growth of LOVO and SW480 cells, while combined 1 µM nicotine treatment notably enhanced cell viability. Overexpression of HMOX1 reversed the 1 µM nicotine-induced increase in cell viability, and the <t>100</t> <t>nM</t> <t>p-NF-κB</t> pathway activator <t>PMA</t> treatment for 24 h partially restored this effect. c-d , k-l The scratch assay and quantitative analysis showed that HMOX1 overexpression reversed the 1 µM nicotine-induced increase in cell migration ability in LOVO and SW480 cells after 24 h of treatment, with 100 nM PMA treatment for 24 h partially restoring this effect. Scale bar = 20 μm. e-h The colony formation assay and quantitative analysis showed that HMOX1 overexpression reversed the 1 µM nicotine-induced enhancement of cell proliferation in LOVO and SW480 cells after 24 h, with 100 nM PMA treatment for 24 h partially restoring this effect. i-j , m-n The invasion assay and quantitative analysis showed that HMOX1 overexpression reversed the 1 µM nicotine-induced increase in cell invasion ability in LOVO and SW480 cells after 24 h of treatment, with 100 nM PMA treatment for 24 h partially restoring this effect. Scale bar = 20 μm. All data are expressed as mean ± standard deviation (independent triplicates). * p < 0.05; ** p < 0.01; *** p < 0.001; ns, no significant difference
    P Nf κb Signaling Pathway Activator Pma, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 96/100, based on 117 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/p nf κb signaling pathway activator pma/product/Selleck Chemicals
    Average 96 stars, based on 117 article reviews
    p nf κb signaling pathway activator pma - by Bioz Stars, 2026-04
    96/100 stars

    Images

    1) Product Images from "Nicotine suppresses ferroptosis in colon cancer cells via HMOX1/NF-κB pathway to reduce oxaliplatin sensitivity"

    Article Title: Nicotine suppresses ferroptosis in colon cancer cells via HMOX1/NF-κB pathway to reduce oxaliplatin sensitivity

    Journal: Apoptosis

    doi: 10.1007/s10495-026-02308-z

    Nicotine reduces the sensitivity of colon cancer cells to oxaliplatin through modulation of the HMOX1/NF-κB signaling pathway. a-b The CCK-8 assay demonstrated that 10 µM oxaliplatin treatment for 24 h significantly inhibited the growth of LOVO and SW480 cells, while combined 1 µM nicotine treatment notably enhanced cell viability. Overexpression of HMOX1 reversed the 1 µM nicotine-induced increase in cell viability, and the 100 nM p-NF-κB pathway activator PMA treatment for 24 h partially restored this effect. c-d , k-l The scratch assay and quantitative analysis showed that HMOX1 overexpression reversed the 1 µM nicotine-induced increase in cell migration ability in LOVO and SW480 cells after 24 h of treatment, with 100 nM PMA treatment for 24 h partially restoring this effect. Scale bar = 20 μm. e-h The colony formation assay and quantitative analysis showed that HMOX1 overexpression reversed the 1 µM nicotine-induced enhancement of cell proliferation in LOVO and SW480 cells after 24 h, with 100 nM PMA treatment for 24 h partially restoring this effect. i-j , m-n The invasion assay and quantitative analysis showed that HMOX1 overexpression reversed the 1 µM nicotine-induced increase in cell invasion ability in LOVO and SW480 cells after 24 h of treatment, with 100 nM PMA treatment for 24 h partially restoring this effect. Scale bar = 20 μm. All data are expressed as mean ± standard deviation (independent triplicates). * p < 0.05; ** p < 0.01; *** p < 0.001; ns, no significant difference
    Figure Legend Snippet: Nicotine reduces the sensitivity of colon cancer cells to oxaliplatin through modulation of the HMOX1/NF-κB signaling pathway. a-b The CCK-8 assay demonstrated that 10 µM oxaliplatin treatment for 24 h significantly inhibited the growth of LOVO and SW480 cells, while combined 1 µM nicotine treatment notably enhanced cell viability. Overexpression of HMOX1 reversed the 1 µM nicotine-induced increase in cell viability, and the 100 nM p-NF-κB pathway activator PMA treatment for 24 h partially restored this effect. c-d , k-l The scratch assay and quantitative analysis showed that HMOX1 overexpression reversed the 1 µM nicotine-induced increase in cell migration ability in LOVO and SW480 cells after 24 h of treatment, with 100 nM PMA treatment for 24 h partially restoring this effect. Scale bar = 20 μm. e-h The colony formation assay and quantitative analysis showed that HMOX1 overexpression reversed the 1 µM nicotine-induced enhancement of cell proliferation in LOVO and SW480 cells after 24 h, with 100 nM PMA treatment for 24 h partially restoring this effect. i-j , m-n The invasion assay and quantitative analysis showed that HMOX1 overexpression reversed the 1 µM nicotine-induced increase in cell invasion ability in LOVO and SW480 cells after 24 h of treatment, with 100 nM PMA treatment for 24 h partially restoring this effect. Scale bar = 20 μm. All data are expressed as mean ± standard deviation (independent triplicates). * p < 0.05; ** p < 0.01; *** p < 0.001; ns, no significant difference

    Techniques Used: CCK-8 Assay, Over Expression, Wound Healing Assay, Migration, Colony Assay, Invasion Assay, Standard Deviation



    Similar Products

    95
    TargetMol cell proliferation
    Cell Proliferation, supplied by TargetMol, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cell proliferation/product/TargetMol
    Average 95 stars, based on 1 article reviews
    cell proliferation - by Bioz Stars, 2026-04
    95/100 stars
      Buy from Supplier

    96
    InvivoGen nf κb signaling pathway thp1 bluetm nf κb reporter cells
    Nf κb Signaling Pathway Thp1 Bluetm Nf κb Reporter Cells, supplied by InvivoGen, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/nf κb signaling pathway thp1 bluetm nf κb reporter cells/product/InvivoGen
    Average 96 stars, based on 1 article reviews
    nf κb signaling pathway thp1 bluetm nf κb reporter cells - by Bioz Stars, 2026-04
    96/100 stars
      Buy from Supplier

    93
    Cell Signaling Technology Inc phosphorylated nf κb p p65 cell signaling
    Phosphorylated Nf κb P P65 Cell Signaling, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/phosphorylated nf κb p p65 cell signaling/product/Cell Signaling Technology Inc
    Average 93 stars, based on 1 article reviews
    phosphorylated nf κb p p65 cell signaling - by Bioz Stars, 2026-04
    93/100 stars
      Buy from Supplier

    96
    Selleck Chemicals p nf κb signaling pathway activator pma
    Nicotine reduces the sensitivity of colon cancer cells to oxaliplatin through modulation of the HMOX1/NF-κB signaling pathway. a-b The CCK-8 assay demonstrated that 10 µM oxaliplatin treatment for 24 h significantly inhibited the growth of LOVO and SW480 cells, while combined 1 µM nicotine treatment notably enhanced cell viability. Overexpression of HMOX1 reversed the 1 µM nicotine-induced increase in cell viability, and the <t>100</t> <t>nM</t> <t>p-NF-κB</t> pathway activator <t>PMA</t> treatment for 24 h partially restored this effect. c-d , k-l The scratch assay and quantitative analysis showed that HMOX1 overexpression reversed the 1 µM nicotine-induced increase in cell migration ability in LOVO and SW480 cells after 24 h of treatment, with 100 nM PMA treatment for 24 h partially restoring this effect. Scale bar = 20 μm. e-h The colony formation assay and quantitative analysis showed that HMOX1 overexpression reversed the 1 µM nicotine-induced enhancement of cell proliferation in LOVO and SW480 cells after 24 h, with 100 nM PMA treatment for 24 h partially restoring this effect. i-j , m-n The invasion assay and quantitative analysis showed that HMOX1 overexpression reversed the 1 µM nicotine-induced increase in cell invasion ability in LOVO and SW480 cells after 24 h of treatment, with 100 nM PMA treatment for 24 h partially restoring this effect. Scale bar = 20 μm. All data are expressed as mean ± standard deviation (independent triplicates). * p < 0.05; ** p < 0.01; *** p < 0.001; ns, no significant difference
    P Nf κb Signaling Pathway Activator Pma, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/p nf κb signaling pathway activator pma/product/Selleck Chemicals
    Average 96 stars, based on 1 article reviews
    p nf κb signaling pathway activator pma - by Bioz Stars, 2026-04
    96/100 stars
      Buy from Supplier

    99
    Cell Signaling Technology Inc phospho nf κb p65 cell signaling technology
    Nicotine reduces the sensitivity of colon cancer cells to oxaliplatin through modulation of the HMOX1/NF-κB signaling pathway. a-b The CCK-8 assay demonstrated that 10 µM oxaliplatin treatment for 24 h significantly inhibited the growth of LOVO and SW480 cells, while combined 1 µM nicotine treatment notably enhanced cell viability. Overexpression of HMOX1 reversed the 1 µM nicotine-induced increase in cell viability, and the <t>100</t> <t>nM</t> <t>p-NF-κB</t> pathway activator <t>PMA</t> treatment for 24 h partially restored this effect. c-d , k-l The scratch assay and quantitative analysis showed that HMOX1 overexpression reversed the 1 µM nicotine-induced increase in cell migration ability in LOVO and SW480 cells after 24 h of treatment, with 100 nM PMA treatment for 24 h partially restoring this effect. Scale bar = 20 μm. e-h The colony formation assay and quantitative analysis showed that HMOX1 overexpression reversed the 1 µM nicotine-induced enhancement of cell proliferation in LOVO and SW480 cells after 24 h, with 100 nM PMA treatment for 24 h partially restoring this effect. i-j , m-n The invasion assay and quantitative analysis showed that HMOX1 overexpression reversed the 1 µM nicotine-induced increase in cell invasion ability in LOVO and SW480 cells after 24 h of treatment, with 100 nM PMA treatment for 24 h partially restoring this effect. Scale bar = 20 μm. All data are expressed as mean ± standard deviation (independent triplicates). * p < 0.05; ** p < 0.01; *** p < 0.001; ns, no significant difference
    Phospho Nf κb P65 Cell Signaling Technology, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/phospho nf κb p65 cell signaling technology/product/Cell Signaling Technology Inc
    Average 99 stars, based on 1 article reviews
    phospho nf κb p65 cell signaling technology - by Bioz Stars, 2026-04
    99/100 stars
      Buy from Supplier

    95
    MedChemExpress nf κb signaling pathway
    DEP increases ITA production by inducing metabolic reprogramming in neutrophils. (A) Heatmap of differentially accumulated metabolites between control and HDM/DEP groups, and the change of ITA between control and HDM/DEP groups in the sequencing data. (B) Volcano plot of the differentially expressed genes between the control and HDM/DEP groups. (C) The levels of ITA measured by LC/MS in BALF and lung tissues of HDM/DEP-induced asthma (n = 6-8 mice per group). (D) Real-time qPCR analysis of Acod1 mRNA expression in the lung tissues of HDM/DEP-induced asthma (n = 4 mice per group). (E) Uniform manifold approximation and projection (UMAP) plot showing 13 clusters of cells in the lung tissues. (F) The percentage of the 13 clusters of cells in the lung tissues of con, HDM, and HDM/DEP groups. (G) The expression of Acod1 in different cell clusters. (H) Violin plot of the expression of Acod1 in different cell clusters. (I) Representative immunofluorescence staining of ACOD1 in the lung tissues of DEP-exposed asthmatic mice. Ly6G was used to mark neutrophils, and CD68 to mark macrophages. ACOD1 was co-localized with neutrophils. Scale bar, 20 μm. (J) Real-time qPCR analysis of Acod1 mRNA expression in BMDNs treated with DEP. (K) Representative immunofluorescence staining of ACOD1 in BMDNs treated with DEP. Scale bar, 10 μm. (L) Intracellular and extracellular levels of ITA measured by LC/MS in DEP-stimulated BMDNs. (M) Representative immunofluorescence staining of ACOD1 in cell pellets of BALF from healthy control and patients with severe asthma. Neutrophils were marked with CD16b, and macrophages were marked with CD68. ACOD1 was co-localized with neutrophils. Scale bar, 10 μm. (N) Real-time qPCR analysis of ACOD1 mRNA expression in PBNs stimulated with DEP. (O) Intracellular and extracellular levels of ITA measured by LC/MS in DEP-stimulated PBNs. (P) Integrated analysis of metabolomics and transcriptomics. (Q) Western blot analysis of TLRs <t>and</t> <t>NF-κB</t> signaling pathways in DEP-treated BMDNs. (R) Real-time qPCR analysis of Acod1 mRNA expression in DEP-stimulated BMDNs pre-treated with TLR2 <t>inhibitor</t> <t>(C29),</t> TLR4 inhibitor (TAK-242), and NF-κB inhibitor (BTZ). ** P < 0.01, compared with the control group; ## P < 0.01, ### P < 0.001, compared with the DEP group. (S) Western blot analysis of ACOD1 expression in DEP-stimulated BMDNs pre-treated with TLR2 inhibitor (C29), TLR4 inhibitor (TAK-242), and NF-κB inhibitor (BTZ). Data are presented as means ± SEM. ** P < 0.01, *** P < 0.001. HDM, house dust mite; DEP, diesel exhaust particles; LC/MS, Liquid Chromatography-Mass Spectrometry; BALF, bronchoalveolar lavage fluid; ACOD1, aconitate decarboxylase 1; BMDNs, bone marrow-derived neutrophils; PBNs, peripheral blood neutrophils; TLR, toll-like receptor; BTZ, Bortezomib.
    Nf κb Signaling Pathway, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/nf κb signaling pathway/product/MedChemExpress
    Average 95 stars, based on 1 article reviews
    nf κb signaling pathway - by Bioz Stars, 2026-04
    95/100 stars
      Buy from Supplier

    94
    BPS Bioscience gitr nfkb luciferase jurkat cell line gitrl gitr mediated nfκb signaling
    DEP increases ITA production by inducing metabolic reprogramming in neutrophils. (A) Heatmap of differentially accumulated metabolites between control and HDM/DEP groups, and the change of ITA between control and HDM/DEP groups in the sequencing data. (B) Volcano plot of the differentially expressed genes between the control and HDM/DEP groups. (C) The levels of ITA measured by LC/MS in BALF and lung tissues of HDM/DEP-induced asthma (n = 6-8 mice per group). (D) Real-time qPCR analysis of Acod1 mRNA expression in the lung tissues of HDM/DEP-induced asthma (n = 4 mice per group). (E) Uniform manifold approximation and projection (UMAP) plot showing 13 clusters of cells in the lung tissues. (F) The percentage of the 13 clusters of cells in the lung tissues of con, HDM, and HDM/DEP groups. (G) The expression of Acod1 in different cell clusters. (H) Violin plot of the expression of Acod1 in different cell clusters. (I) Representative immunofluorescence staining of ACOD1 in the lung tissues of DEP-exposed asthmatic mice. Ly6G was used to mark neutrophils, and CD68 to mark macrophages. ACOD1 was co-localized with neutrophils. Scale bar, 20 μm. (J) Real-time qPCR analysis of Acod1 mRNA expression in BMDNs treated with DEP. (K) Representative immunofluorescence staining of ACOD1 in BMDNs treated with DEP. Scale bar, 10 μm. (L) Intracellular and extracellular levels of ITA measured by LC/MS in DEP-stimulated BMDNs. (M) Representative immunofluorescence staining of ACOD1 in cell pellets of BALF from healthy control and patients with severe asthma. Neutrophils were marked with CD16b, and macrophages were marked with CD68. ACOD1 was co-localized with neutrophils. Scale bar, 10 μm. (N) Real-time qPCR analysis of ACOD1 mRNA expression in PBNs stimulated with DEP. (O) Intracellular and extracellular levels of ITA measured by LC/MS in DEP-stimulated PBNs. (P) Integrated analysis of metabolomics and transcriptomics. (Q) Western blot analysis of TLRs <t>and</t> <t>NF-κB</t> signaling pathways in DEP-treated BMDNs. (R) Real-time qPCR analysis of Acod1 mRNA expression in DEP-stimulated BMDNs pre-treated with TLR2 <t>inhibitor</t> <t>(C29),</t> TLR4 inhibitor (TAK-242), and NF-κB inhibitor (BTZ). ** P < 0.01, compared with the control group; ## P < 0.01, ### P < 0.001, compared with the DEP group. (S) Western blot analysis of ACOD1 expression in DEP-stimulated BMDNs pre-treated with TLR2 inhibitor (C29), TLR4 inhibitor (TAK-242), and NF-κB inhibitor (BTZ). Data are presented as means ± SEM. ** P < 0.01, *** P < 0.001. HDM, house dust mite; DEP, diesel exhaust particles; LC/MS, Liquid Chromatography-Mass Spectrometry; BALF, bronchoalveolar lavage fluid; ACOD1, aconitate decarboxylase 1; BMDNs, bone marrow-derived neutrophils; PBNs, peripheral blood neutrophils; TLR, toll-like receptor; BTZ, Bortezomib.
    Gitr Nfkb Luciferase Jurkat Cell Line Gitrl Gitr Mediated Nfκb Signaling, supplied by BPS Bioscience, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/gitr nfkb luciferase jurkat cell line gitrl gitr mediated nfκb signaling/product/BPS Bioscience
    Average 94 stars, based on 1 article reviews
    gitr nfkb luciferase jurkat cell line gitrl gitr mediated nfκb signaling - by Bioz Stars, 2026-04
    94/100 stars
      Buy from Supplier

    Image Search Results


    Nicotine reduces the sensitivity of colon cancer cells to oxaliplatin through modulation of the HMOX1/NF-κB signaling pathway. a-b The CCK-8 assay demonstrated that 10 µM oxaliplatin treatment for 24 h significantly inhibited the growth of LOVO and SW480 cells, while combined 1 µM nicotine treatment notably enhanced cell viability. Overexpression of HMOX1 reversed the 1 µM nicotine-induced increase in cell viability, and the 100 nM p-NF-κB pathway activator PMA treatment for 24 h partially restored this effect. c-d , k-l The scratch assay and quantitative analysis showed that HMOX1 overexpression reversed the 1 µM nicotine-induced increase in cell migration ability in LOVO and SW480 cells after 24 h of treatment, with 100 nM PMA treatment for 24 h partially restoring this effect. Scale bar = 20 μm. e-h The colony formation assay and quantitative analysis showed that HMOX1 overexpression reversed the 1 µM nicotine-induced enhancement of cell proliferation in LOVO and SW480 cells after 24 h, with 100 nM PMA treatment for 24 h partially restoring this effect. i-j , m-n The invasion assay and quantitative analysis showed that HMOX1 overexpression reversed the 1 µM nicotine-induced increase in cell invasion ability in LOVO and SW480 cells after 24 h of treatment, with 100 nM PMA treatment for 24 h partially restoring this effect. Scale bar = 20 μm. All data are expressed as mean ± standard deviation (independent triplicates). * p < 0.05; ** p < 0.01; *** p < 0.001; ns, no significant difference

    Journal: Apoptosis

    Article Title: Nicotine suppresses ferroptosis in colon cancer cells via HMOX1/NF-κB pathway to reduce oxaliplatin sensitivity

    doi: 10.1007/s10495-026-02308-z

    Figure Lengend Snippet: Nicotine reduces the sensitivity of colon cancer cells to oxaliplatin through modulation of the HMOX1/NF-κB signaling pathway. a-b The CCK-8 assay demonstrated that 10 µM oxaliplatin treatment for 24 h significantly inhibited the growth of LOVO and SW480 cells, while combined 1 µM nicotine treatment notably enhanced cell viability. Overexpression of HMOX1 reversed the 1 µM nicotine-induced increase in cell viability, and the 100 nM p-NF-κB pathway activator PMA treatment for 24 h partially restored this effect. c-d , k-l The scratch assay and quantitative analysis showed that HMOX1 overexpression reversed the 1 µM nicotine-induced increase in cell migration ability in LOVO and SW480 cells after 24 h of treatment, with 100 nM PMA treatment for 24 h partially restoring this effect. Scale bar = 20 μm. e-h The colony formation assay and quantitative analysis showed that HMOX1 overexpression reversed the 1 µM nicotine-induced enhancement of cell proliferation in LOVO and SW480 cells after 24 h, with 100 nM PMA treatment for 24 h partially restoring this effect. i-j , m-n The invasion assay and quantitative analysis showed that HMOX1 overexpression reversed the 1 µM nicotine-induced increase in cell invasion ability in LOVO and SW480 cells after 24 h of treatment, with 100 nM PMA treatment for 24 h partially restoring this effect. Scale bar = 20 μm. All data are expressed as mean ± standard deviation (independent triplicates). * p < 0.05; ** p < 0.01; *** p < 0.001; ns, no significant difference

    Article Snippet: Iron death inducer RSL3 (Selleck, USA) and p-NF-κB signaling pathway activator PMA (Phorbol 12-myristate 13-acetate, Selleck, USA) were dissolved in DMSO to prepare stock solutions, stored at -20 °C in a dark environment, and diluted to working concentrations before use for cell treatment according to the experimental design.

    Techniques: CCK-8 Assay, Over Expression, Wound Healing Assay, Migration, Colony Assay, Invasion Assay, Standard Deviation

    DEP increases ITA production by inducing metabolic reprogramming in neutrophils. (A) Heatmap of differentially accumulated metabolites between control and HDM/DEP groups, and the change of ITA between control and HDM/DEP groups in the sequencing data. (B) Volcano plot of the differentially expressed genes between the control and HDM/DEP groups. (C) The levels of ITA measured by LC/MS in BALF and lung tissues of HDM/DEP-induced asthma (n = 6-8 mice per group). (D) Real-time qPCR analysis of Acod1 mRNA expression in the lung tissues of HDM/DEP-induced asthma (n = 4 mice per group). (E) Uniform manifold approximation and projection (UMAP) plot showing 13 clusters of cells in the lung tissues. (F) The percentage of the 13 clusters of cells in the lung tissues of con, HDM, and HDM/DEP groups. (G) The expression of Acod1 in different cell clusters. (H) Violin plot of the expression of Acod1 in different cell clusters. (I) Representative immunofluorescence staining of ACOD1 in the lung tissues of DEP-exposed asthmatic mice. Ly6G was used to mark neutrophils, and CD68 to mark macrophages. ACOD1 was co-localized with neutrophils. Scale bar, 20 μm. (J) Real-time qPCR analysis of Acod1 mRNA expression in BMDNs treated with DEP. (K) Representative immunofluorescence staining of ACOD1 in BMDNs treated with DEP. Scale bar, 10 μm. (L) Intracellular and extracellular levels of ITA measured by LC/MS in DEP-stimulated BMDNs. (M) Representative immunofluorescence staining of ACOD1 in cell pellets of BALF from healthy control and patients with severe asthma. Neutrophils were marked with CD16b, and macrophages were marked with CD68. ACOD1 was co-localized with neutrophils. Scale bar, 10 μm. (N) Real-time qPCR analysis of ACOD1 mRNA expression in PBNs stimulated with DEP. (O) Intracellular and extracellular levels of ITA measured by LC/MS in DEP-stimulated PBNs. (P) Integrated analysis of metabolomics and transcriptomics. (Q) Western blot analysis of TLRs and NF-κB signaling pathways in DEP-treated BMDNs. (R) Real-time qPCR analysis of Acod1 mRNA expression in DEP-stimulated BMDNs pre-treated with TLR2 inhibitor (C29), TLR4 inhibitor (TAK-242), and NF-κB inhibitor (BTZ). ** P < 0.01, compared with the control group; ## P < 0.01, ### P < 0.001, compared with the DEP group. (S) Western blot analysis of ACOD1 expression in DEP-stimulated BMDNs pre-treated with TLR2 inhibitor (C29), TLR4 inhibitor (TAK-242), and NF-κB inhibitor (BTZ). Data are presented as means ± SEM. ** P < 0.01, *** P < 0.001. HDM, house dust mite; DEP, diesel exhaust particles; LC/MS, Liquid Chromatography-Mass Spectrometry; BALF, bronchoalveolar lavage fluid; ACOD1, aconitate decarboxylase 1; BMDNs, bone marrow-derived neutrophils; PBNs, peripheral blood neutrophils; TLR, toll-like receptor; BTZ, Bortezomib.

    Journal: International Journal of Biological Sciences

    Article Title: Itaconate Modulates Neutrophil Homeostasis to Ameliorate Airway Inflammation in Diesel Exhaust Particles-exacerbated Asthma via Inhibiting NETs Formation

    doi: 10.7150/ijbs.124927

    Figure Lengend Snippet: DEP increases ITA production by inducing metabolic reprogramming in neutrophils. (A) Heatmap of differentially accumulated metabolites between control and HDM/DEP groups, and the change of ITA between control and HDM/DEP groups in the sequencing data. (B) Volcano plot of the differentially expressed genes between the control and HDM/DEP groups. (C) The levels of ITA measured by LC/MS in BALF and lung tissues of HDM/DEP-induced asthma (n = 6-8 mice per group). (D) Real-time qPCR analysis of Acod1 mRNA expression in the lung tissues of HDM/DEP-induced asthma (n = 4 mice per group). (E) Uniform manifold approximation and projection (UMAP) plot showing 13 clusters of cells in the lung tissues. (F) The percentage of the 13 clusters of cells in the lung tissues of con, HDM, and HDM/DEP groups. (G) The expression of Acod1 in different cell clusters. (H) Violin plot of the expression of Acod1 in different cell clusters. (I) Representative immunofluorescence staining of ACOD1 in the lung tissues of DEP-exposed asthmatic mice. Ly6G was used to mark neutrophils, and CD68 to mark macrophages. ACOD1 was co-localized with neutrophils. Scale bar, 20 μm. (J) Real-time qPCR analysis of Acod1 mRNA expression in BMDNs treated with DEP. (K) Representative immunofluorescence staining of ACOD1 in BMDNs treated with DEP. Scale bar, 10 μm. (L) Intracellular and extracellular levels of ITA measured by LC/MS in DEP-stimulated BMDNs. (M) Representative immunofluorescence staining of ACOD1 in cell pellets of BALF from healthy control and patients with severe asthma. Neutrophils were marked with CD16b, and macrophages were marked with CD68. ACOD1 was co-localized with neutrophils. Scale bar, 10 μm. (N) Real-time qPCR analysis of ACOD1 mRNA expression in PBNs stimulated with DEP. (O) Intracellular and extracellular levels of ITA measured by LC/MS in DEP-stimulated PBNs. (P) Integrated analysis of metabolomics and transcriptomics. (Q) Western blot analysis of TLRs and NF-κB signaling pathways in DEP-treated BMDNs. (R) Real-time qPCR analysis of Acod1 mRNA expression in DEP-stimulated BMDNs pre-treated with TLR2 inhibitor (C29), TLR4 inhibitor (TAK-242), and NF-κB inhibitor (BTZ). ** P < 0.01, compared with the control group; ## P < 0.01, ### P < 0.001, compared with the DEP group. (S) Western blot analysis of ACOD1 expression in DEP-stimulated BMDNs pre-treated with TLR2 inhibitor (C29), TLR4 inhibitor (TAK-242), and NF-κB inhibitor (BTZ). Data are presented as means ± SEM. ** P < 0.01, *** P < 0.001. HDM, house dust mite; DEP, diesel exhaust particles; LC/MS, Liquid Chromatography-Mass Spectrometry; BALF, bronchoalveolar lavage fluid; ACOD1, aconitate decarboxylase 1; BMDNs, bone marrow-derived neutrophils; PBNs, peripheral blood neutrophils; TLR, toll-like receptor; BTZ, Bortezomib.

    Article Snippet: In some experiments, inhibitors targeting toll-like receptor 2 (TLR2) (C29, 100 μM; MedChemExpress, USA), TLR4 (TAK242, 100 nM; MedChemExpress, USA), the NF-κB signaling pathway (Bortezomib, 50 nM; MedChemExpress, USA), as well as ITA or 4-OI, were administered one hour prior to DEP or LPS treatment.

    Techniques: Control, Sequencing, Liquid Chromatography with Mass Spectroscopy, Expressing, Immunofluorescence, Staining, Transcriptomics, Western Blot, Protein-Protein interactions, Liquid Chromatography, Mass Spectrometry, Derivative Assay